Trial of Lixisenatide in Early Parkinson’s Disease

This phase 2, double blind, randomized, placebo controlled trial evaluated the effect of lixisenatide, a glucagon like peptide 1 receptor agonist, on motor disability progression in early Parkinson’s disease. Participants (n=156) with a diagnosis within the past 3 years were assigned to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2month washout. The primary endpoint was the change in Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores at 12 months. Results showed a significant difference favoring lixisenatide ( 0.04 points vs. +3.04 points with placebo, P=0.007). Gastrointestinal side effects were common (46% nausea, 13% vomiting). The findings suggest lixisenatide may slow motor disability progression, warranting further investigation in larger trials.

This phase 2, double blind, randomized, placebo controlled trial evaluated the effect of lixisenatide, a glucagon like peptide 1 receptor agonist, on motor disability progression in early Parkinson’s disease. Participants (n=156) with a diagnosis within the past 3 years were assigned to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2month washout. The primary endpoint was the change in Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores at 12 months. Results showed a significant difference favoring lixisenatide ( 0.04 points vs. +3.04 points with placebo, P=0.007). Gastrointestinal side effects were common (46% nausea, 13% vomiting). The findings suggest lixisenatide may slow motor disability progression, warranting further investigation in larger trials.